About this Research Topic
Pediatric glioma treatment has seen significant advancements in recent years, with a deeper understanding of glioma biology leading to the development of new therapeutic interventions. However, the current therapeutic approaches have only been partially effective, with pediatric-type diffuse high-grade glioma remaining virtually incurable. While most pediatric low-grade gliomas can be cured surgically, a small minority require multiple lines of treatment due to persistent progression. The interplay between driver mutations, the tumor microenvironment, immune regulation, and other mutations is complex and requires further investigation. Despite these challenges, recent breakthroughs in targeted therapies, immune checkpoint inhibition, vaccine therapy, and other immunotherapies have shown promise in increasing progression-free survival.
The primary aim of this research topic is to summarize the fundamental scientific achievements that have led to the current era of increased treatment options for pediatric glioma. This includes presenting early pre-clinical and clinical results in immunotherapies for pediatric high-grade glioma, such as T-cell therapies, vaccine-based therapies, and immune checkpoint therapies, as well as targeted therapies for both high-grade and low-grade gliomas. The goal is to provide clinicians with the necessary context to help them and their patients navigate the increasingly complex decision-making process of choosing between approved therapies and clinical trials.
The scope of this research topic is focused on new therapeutic approaches for pediatric glioma, with a particular emphasis on pre-clinical and clinical studies. We welcome articles addressing, but not limited to, the following themes:
- The role of Next Generation Sequencing in identifying driver mutations in tumors
- The interplay between driver mutations, the tumor microenvironment, and immune regulation
- The effectiveness of recent breakthroughs in targeted therapies, immune checkpoint inhibition, vaccine therapy, and other immunotherapies
- The challenges and potential solutions in treating pediatric-type diffuse high-grade glioma
- The decision-making process for clinicians in choosing between approved therapies and clinical trials.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The primary aim of this research topic is to summarize the fundamental scientific achievements that have led to the current era of increased treatment options for pediatric glioma. This includes presenting early pre-clinical and clinical results in immunotherapies for pediatric high-grade glioma, such as T-cell therapies, vaccine-based therapies, and immune checkpoint therapies, as well as targeted therapies for both high-grade and low-grade gliomas. The goal is to provide clinicians with the necessary context to help them and their patients navigate the increasingly complex decision-making process of choosing between approved therapies and clinical trials.
The scope of this research topic is focused on new therapeutic approaches for pediatric glioma, with a particular emphasis on pre-clinical and clinical studies. We welcome articles addressing, but not limited to, the following themes:
- The role of Next Generation Sequencing in identifying driver mutations in tumors
- The interplay between driver mutations, the tumor microenvironment, and immune regulation
- The effectiveness of recent breakthroughs in targeted therapies, immune checkpoint inhibition, vaccine therapy, and other immunotherapies
- The challenges and potential solutions in treating pediatric-type diffuse high-grade glioma
- The decision-making process for clinicians in choosing between approved therapies and clinical trials.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: Clinical Outcomes, Pediatric Gliomas, Immunotherapy, T-cell Therapy, Vaccine-Based Therapy, Immune Checkpoint therapy, Targeted Therapy, Decision-Making
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
